Lb Pharmaceuticals (LBRX) Share-based Compensation (2024 - 2026)

Lb Pharmaceuticals has reported Share-based Compensation for 3 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 304.73% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $5.7 million (changed N/A YoY), and the FY2025 full-year result was $4.2 million, up 5802.82% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.6 million, up from $2.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $2.6 million in Q1 2026, with the low at $1000.0 in Q3 2024.
• Average Share-based Compensation over 3 years is $1.1 million, with a median of $634000.0 recorded in 2025.
• Year-over-year, Share-based Compensation jumped 11200.0% in 2025 and soared 304.73% in 2026.
• Tracing LBRX's Share-based Compensation over 3 years: stood at $1000.0 in 2024, then surged by 234000.0% to $2.3 million in 2025, then climbed by 9.61% to $2.6 million in 2026.
• The last three Share-based Compensation figures came in at $2.6 million (Q1 2026), $2.3 million (Q4 2025), and $113000.0 (Q3 2025), per Business Quant data.

Peer Comparison